Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 141 Breast Neoplasms 10 Neoplasm Metastasis 8 Neoplasms 5 Bulbo-Spinal Atrophy, X-Linked 5 Triple Negative Breast Neoplasms 4 Salivary Gland Neoplasms 3 Prostate Adenocarcinoma 2 Osteoporosis 2 Lower Urinary Tract Symptoms 2 Hirsutism 2 Thrombocytosis 1 Stage I Prostate Adenocarcinoma AJCC v7 1 Stage I Prostate Adenocarcinoma 1 Sexual Dysfunction, Physiological 1 Recurrence 1 Primary Myelofibrosis 1 Primary Dysautonomias 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paget Disease, Extramammary 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Non-Muscle Invasive Bladder Urothelial Carcinoma 1 Non-Muscle Invasive Bladder Neoplasms 1 Non Castrate Metastatic Prostate Cancer 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1

Interventions

pembrolizumab 91 Gemcitabine 56 Nivolumab 50 Cisplatin 39 atezolizumab 37 Carboplatin 30 avelumab 29 enfortumab vedotin 25 Docetaxel 23 Magnetic Resonance Spectroscopy 19 Mitomycin 17 Ipilimumab 17 Paclitaxel 16 Specimen Handling 14 durvalumab 11 toripalimab 10 sacituzumab govitecan 10 Pemetrexed 10 cabozantinib 9 Taxes 8 vinflunine 7 Cyclophosphamide 7 tislelizumab 6 Injections 6 Bevacizumab 6 pemigatinib 5 fludarabine 5 disitamab vedotin 5 Standard of Care 5 Radiosurgery 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × bicalutamide × Clear all

NCT06018116 2024-02-15

CANUCK-01

CHU de Quebec-Universite Laval

Phase 2 Withdrawn

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡